HZ-S109 / HealZen Therap - LARVOL DELTA

HZ-S109, a potent and selective HPK1 degrader with enhanced T cell modulation efficacy and improved bioavailability (AACR 2025) - "HZ-S109 exhibits potent HPK1 degradation with DC50 values lower than 10 nM across various cell types, including Jurkat, Ramos, PBMC, and CAR-T cells. Importantly, HZ-S109 demonstrated no significant effect on other family members, such as GCK, GLK, HGK, or KHS. HZ-S109 can significantly enhance the activation of primary T cell at nanomolar level concentrations, with the maximum activation fold exceeding 15-fold."

Clinical • Oncology • LCP2 • TGFB1